Literature DB >> 34301306

The lungs were on fire: a pilot study of 18F-FDG PET/CT in idiopathic-inflammatory-myopathy-related interstitial lung disease.

Junyu Liang1, Heng Cao1, Yinuo Liu2, Bingjue Ye3, Yiduo Sun1, Yini Ke1, Ye He1, Bei Xu1, Jin Lin4.   

Abstract

BACKGROUND: Interstitial lung disease (ILD) and its rapid progression (RP) are the main contributors to unfavourable outcomes of patients with idiopathic inflammatory myopathy (IIM). This study aimed to identify the clinical value of PET/CT scans in IIM-ILD patients and to construct a predictive model for RP-ILD.
METHODS: Adult IIM-ILD patients who were hospitalized at four divisions of the First Affiliated Hospital, Zhejiang University School of Medicine (FAHZJU), from 1 January 2017 to 31 December 2020 were reviewed. PET/CT scans and other characteristics of patients who met the inclusion and exclusion criteria were collected and analysed.
RESULTS: A total of 61 IIM-ILD patients were enrolled in this study. Twenty-one patients (34.4%) developed RP-ILD, and 24 patients (39.3%) died during follow-up. After false discovery rate (FDR) correction, the percent-predicted diffusing capacity of the lung for carbon monoxide (DLCO%, P = 0.014), bilateral lung mean standard uptake value (SUVmean, P = 0.014) and abnormal mediastinal lymph node (P = 0.045) were significantly different between the RP-ILD and non-RP-ILD groups. The subsequent univariate and multivariate logistic regression analyses verified our findings. A "DLM" model was established by including the above three values to predict RP-ILD with a cut-off value of ≥ 2 and an area under the curve (AUC) of 0.905. Higher bilateral lung SUVmean (P = 0.019) and spleen SUVmean (P = 0.011) were observed in IIM-ILD patients who died within 3 months, and a moderate correlation was recognized between the two values.
CONCLUSIONS: Elevated bilateral lung SUVmean, abnormal mediastinal lymph nodes and decreased DLCO% were significantly associated with RP-ILD in IIM-ILD patients. The "DLM" model was valuable in predicting RP-ILD and requires further validation.
© 2021. The Author(s).

Entities:  

Keywords:  Dermatomyositis; Idiopathic inflammatory myopathy; Interstitial lung disease; PET/CT scan; Polymyositis

Year:  2021        PMID: 34301306     DOI: 10.1186/s13075-021-02578-9

Source DB:  PubMed          Journal:  Arthritis Res Ther        ISSN: 1478-6354            Impact factor:   5.156


  36 in total

1.  The spatial landscape of lung pathology during COVID-19 progression.

Authors:  André F Rendeiro; Hiranmayi Ravichandran; Yaron Bram; Vasuretha Chandar; Junbum Kim; Cem Meydan; Jiwoon Park; Jonathan Foox; Tyler Hether; Sarah Warren; Youngmi Kim; Jason Reeves; Steven Salvatore; Christopher E Mason; Eric C Swanson; Alain C Borczuk; Olivier Elemento; Robert E Schwartz
Journal:  Nature       Date:  2021-03-29       Impact factor: 49.962

2.  Treatment of idiopathic inflammatory myositis associated interstitial lung disease: A systematic review and meta-analysis.

Authors:  Thomas Barba; Romain Fort; Vincent Cottin; Steeve Provencher; Isabelle Durieu; Sabine Jardel; Arnaud Hot; Quitterie Reynaud; Jean-Christophe Lega
Journal:  Autoimmun Rev       Date:  2018-12-17       Impact factor: 9.754

3.  Combined anti-fibrotic and anti-inflammatory properties of JAK-inhibitors on macrophages in vitro and in vivo: Perspectives for scleroderma-associated interstitial lung disease.

Authors:  Alain Lescoat; Marie Lelong; Mohamed Jeljeli; Claire Piquet-Pellorce; Claudie Morzadec; Alice Ballerie; Stéphane Jouneau; Patrick Jego; Laurent Vernhet; Fréderic Batteux; Olivier Fardel; Valérie Lecureur
Journal:  Biochem Pharmacol       Date:  2020-06-17       Impact factor: 5.858

Review 4.  Recognition and Management of Myositis-Associated Rapidly Progressive Interstitial Lung Disease.

Authors:  Renea Jablonski; Sangeeta Bhorade; Mary E Strek; Jane Dematte
Journal:  Chest       Date:  2020-02-12       Impact factor: 9.410

Review 5.  Inflammation and immunity in IPF pathogenesis and treatment.

Authors:  P Heukels; C C Moor; J H von der Thüsen; M S Wijsenbeek; M Kool
Journal:  Respir Med       Date:  2019-01-09       Impact factor: 3.415

6.  Risk Prediction Modeling Based on a Combination of Initial Serum Biomarker Levels in Polymyositis/Dermatomyositis-Associated Interstitial Lung Disease.

Authors:  Takahisa Gono; Kenichi Masui; Naoshi Nishina; Yasushi Kawaguchi; Atsushi Kawakami; Kei Ikeda; Yohei Kirino; Yumiko Sugiyama; Yoshinori Tanino; Takahiro Nunokawa; Yuko Kaneko; Shinji Sato; Katsuaki Asakawa; Taro Ukichi; Shinjiro Kaieda; Taio Naniwa; Yutaka Okano; Masataka Kuwana
Journal:  Arthritis Rheumatol       Date:  2021-02-22       Impact factor: 10.995

7.  Multicenter Prospective Study of the Efficacy and Safety of Combined Immunosuppressive Therapy With High-Dose Glucocorticoid, Tacrolimus, and Cyclophosphamide in Interstitial Lung Diseases Accompanied by Anti-Melanoma Differentiation-Associated Gene 5-Positive Dermatomyositis.

Authors:  Hideaki Tsuji; Ran Nakashima; Yuji Hosono; Yoshitaka Imura; Masato Yagita; Hajime Yoshifuji; Shintaro Hirata; Takaki Nojima; Eiji Sugiyama; Kazuhiro Hatta; Yoshio Taguchi; Masaki Katayama; Kiminobu Tanizawa; Tomohiro Handa; Ryuji Uozumi; Shuji Akizuki; Kosaku Murakami; Motomu Hashimoto; Masao Tanaka; Koichiro Ohmura; Tsuneyo Mimori
Journal:  Arthritis Rheumatol       Date:  2020-01-27       Impact factor: 10.995

8.  Clinical significance of soluble CD163 in polymyositis-related or dermatomyositis-related interstitial lung disease.

Authors:  Yasunori Enomoto; Yuzo Suzuki; Hironao Hozumi; Kazutaka Mori; Masato Kono; Masato Karayama; Kazuki Furuhashi; Tomoyuki Fujisawa; Noriyuki Enomoto; Yutaro Nakamura; Naoki Inui; Daisuke Suzuki; Noriyoshi Ogawa; Ran Nakashima; Tsuneyo Mimori; Toshihide Iwashita; Takafumi Suda
Journal:  Arthritis Res Ther       Date:  2017-01-19       Impact factor: 5.156

9.  The predictive prognostic factors for polymyositis/dermatomyositis-associated interstitial lung disease.

Authors:  Yumiko Sugiyama; Ryusuke Yoshimi; Maasa Tamura; Mitsuhiro Takeno; Yosuke Kunishita; Daiga Kishimoto; Yuji Yoshioka; Kouji Kobayashi; Kaoru Takase-Minegishi; Toshiyuki Watanabe; Naoki Hamada; Hideto Nagai; Naomi Tsuchida; Yutaro Soejima; Hiroto Nakano; Reikou Kamiyama; Takeaki Uehara; Yohei Kirino; Akiko Sekiguchi; Atsushi Ihata; Shigeru Ohno; Shouhei Nagaoka; Hideaki Nakajima
Journal:  Arthritis Res Ther       Date:  2018-01-11       Impact factor: 5.156

10.  Predictive Features and Clinical Presentation of Interstitial Lung Disease in Inflammatory Myositis.

Authors:  Tamara Vojinovic; Ilaria Cavazzana; Paolo Ceruti; Micaela Fredi; Denise Modina; Marialma Berlendis; Franco Franceschini
Journal:  Clin Rev Allergy Immunol       Date:  2020-11-03       Impact factor: 8.667

View more
  2 in total

1.  18F-FDG PET/CT and HRCT: a combined tool for risk stratification in idiopathic inflammatory myopathy-associated interstitial lung disease.

Authors:  Yuying Zhang; Zhifeng Chen; Yali Long; Bing Zhang; Qiao He; Kejing Tang; Xiangsong Zhang
Journal:  Clin Rheumatol       Date:  2022-06-27       Impact factor: 3.650

Review 2.  The Role of Quantitative and Semi-quantitative [18F]FDG-PET/CT Indices for Evaluating Disease Activity and Management of Patients With Dermatomyositis and Polymyositis.

Authors:  Halil Yildiz; Philippe D'abadie; Olivier Gheysens
Journal:  Front Med (Lausanne)       Date:  2022-04-15
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.